Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial
Participants with active PsA and complex inflammatory-metabolic disease achieved clinically meaningful improvement of PsA, physical function, weight reduction, and quality of life when treated with IXE + TZP compared to IXE alone, with no new safety concerns.
Authors
- Cynthia E. Kartman (ORCID: https://orcid.org/0000-0002-5711-0441)
- Purvi Prajapati (ORCID: https://orcid.org/0000-0002-4102-9542)
- Andris Kronbergs
- Luna Sun
- Peter Fischer (ORCID: https://orcid.org/0000-0002-2992-5037)
- Mark C. Genovese (ORCID: https://orcid.org/0000-0001-5294-4503)
- Laura C. Coates
- Píndaro Martínez‐Osuna
- Joseph F. Merola
- Anabela Cardoso
- Alan Kivitz
- Naveed Sattar
- Philip Mease
- Alexis Ogdie
- Daniel Aletaha
Institutions
- Eli Lilly (United States) (US)
- Nuffield Orthopaedic Centre (GB)
- Swedish Medical Center (US)
- Southwestern Medical Center (US)
- Altoona Center for Clinical Research (US)
- Medical University of Vienna (AT)
- University of Glasgow (GB)
- University of Pennsylvania (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2026-03-28
- DOI
- https://doi.org/10.1002/art.70134
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00